Bio-Techne Quarterly Income Statement
NASDAQ: TECHHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bio-Techne revenue and earnings
In the quarter ended Jun 30, 2026, Bio-Techne generated $321.2 million in revenue, up 1.3% from the same quarter a year earlier. Net income was $54.6 million, for a net margin of 17.0% versus a median of 12.8% in the prior 5 quarters. Gross margin was 65.8% (up from 62.7%) and operating margin 23.1%.
Diluted earnings per share came in at $0.36.
Summary generated from market data by MetaCap's automated system. Methodology
Bio-Techne income statement (quarterly)
| Quarter (USD) | Q4 20262026-06-30 | Q3 20262026-03-31 | Q2 20262025-12-31 | Q1 20262025-09-30 | Q4 20252025-06-30 | Q3 20252025-03-31 | Q2 20252024-12-31 | Q1 20252024-09-30 | Q4 20242024-06-30 | Q3 20242024-03-31 | Q2 20242023-12-31 | Q1 20242023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 321.19M | 311.42M | 295.88M | 286.56M | 316.96M | 316.18M | 297.03M | 289.46M | 306.10M | 303.43M | 272.60M | 276.94M |
| Revenue growth (YoY) | +1.33% | -1.51% | -0.39% | -1.00% | +3.55% | +4.20% | +8.96% | +4.52% | +1.59% | +3.16% | +0.37% | +2.70% |
| Cost of Revenue | 109.80M | 103.13M | 104.60M | 98.44M | 118.15M | 101.63M | 103.14M | 106.44M | 102.75M | 98.83M | 96.01M | 91.74M |
| Gross Profit | 211.39M | 208.29M | 191.28M | 188.11M | 198.81M | 214.56M | 193.89M | 183.02M | 203.35M | 204.60M | 176.59M | 185.19M |
| Operating Expenses | 137.12M | 132.79M | 136.82M | 140.45M | 222.67M | 175.85M | 146.47M | 143.03M | 157.53M | 137.60M | 138.58M | 129.33M |
| Research & Development | 23.95M | 23.45M | 23.13M | 24.24M | 26.03M | 24.58M | 25.02M | 23.87M | 23.99M | 25.76M | 22.92M | 24.00M |
| Selling, General & Admin | 113.17M | 109.34M | 113.69M | 116.21M | 196.64M | 151.27M | 121.45M | 119.16M | 133.54M | 111.84M | 115.67M | 105.33M |
| Operating Income | 74.28M | 75.50M | 54.46M | 47.66M | -23.86M | 38.71M | 47.42M | 39.99M | 45.82M | 67.00M | 38.00M | 55.86M |
| Interest Expense | 2.12M | 2.40M | 2.17M | 2.93M | 2.18M | 2.01M | 2.15M | 2.18M | 2.51M | 4.00M | 4.33M | 4.89M |
| Other Income (Expense) | -3.60M | -4.27M | -3.68M | 333.00K | 1.00M | -434.00K | -4.54M | 184.00K | -4.16M | -5.91M | -4.62M | -6.30M |
| Pretax Income | 70.68M | 71.22M | 50.78M | 47.99M | -22.86M | 38.27M | 42.88M | 40.17M | 41.66M | 61.08M | 33.39M | 49.56M |
| Income Tax | 16.06M | 20.18M | 12.78M | 9.81M | -5.18M | 15.69M | 7.99M | 6.57M | 1.07M | 12.03M | 5.92M | -1.44M |
| Net Income | 54.62M | 51.05M | 38.01M | 38.19M | -17.68M | 22.59M | 34.89M | 33.60M | 40.59M | 49.06M | 27.46M | 50.99M |
| Net Income growth (YoY) | — | +125.99% | +8.94% | +13.65% | -143.55% | -53.96% | +27.03% | -34.11% | -46.23% | -30.13% | -45.08% | -43.06% |
| EPS (Basic) | 0.35 | 0.33 | 0.24 | 0.25 | -0.10 | 0.14 | 0.22 | 0.21 | 0.27 | 0.31 | 0.17 | 0.32 |
| EPS (Diluted) | 0.36 | 0.32 | 0.24 | 0.24 | -0.11 | 0.14 | 0.22 | 0.21 | 0.26 | 0.31 | 0.17 | 0.31 |
| Shares Outstanding (Basic) | — | 156.33M | 155.84M | 155.46M | — | 157.37M | 158.43M | 158.53M | — | 157.31M | 157.53M | 158.13M |
| Shares Outstanding (Diluted) | — | 157.40M | 157.00M | 156.36M | — | 158.94M | 160.63M | 161.12M | — | 160.50M | 160.06M | 161.94M |
| EBITDA | 98.42M | 99.66M | 79.17M | 72.00M | 3.25M | 66.28M | 74.50M | 68.12M | 73.88M | 94.31M | 65.81M | 84.40M |
| Gross Margin | 65.82% | 66.88% | 64.65% | 65.65% | 62.72% | 67.86% | 65.27% | 63.23% | 66.43% | 67.43% | 64.78% | 66.87% |
| Operating Margin | 23.13% | 24.24% | 18.41% | 16.63% | -7.53% | 12.24% | 15.96% | 13.81% | 14.97% | 22.08% | 13.94% | 20.17% |
| Net Margin | 17.01% | 16.39% | 12.85% | 13.33% | -5.58% | 7.14% | 11.75% | 11.61% | 13.26% | 16.17% | 10.08% | 18.41% |
This table shows 12 quarterly periods of Bio-Techne's income statement, from Q4 2026 back to Q1 2024, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TECH's reporting calendar. What is a income statement?